In heart failure with reduced ejection fraction (HFrEF), the pillars of GDMT include beta-blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)/angiotensin receptor and neprilysin inhibitors (ARNI), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 (SGLT2) inhibitors [31]. Here, SLC5A2 is linked to heart failure.